Brief: Lucid Diagnostics' Esoguard BE-1 Prospective Multicenter Clinical Validation Study Of Esoguard Esophageal Precancer Testing Accepted For Peer-Reviewed Publication
07/11/2024 13:10
Nov 7 (Reuters) - Lucid Group Inc LCID.O :
* LUCID DIAGNOSTICS' ESOGUARD BE-1 PROSPECTIVE MULTICENTER
CLINICAL VALIDATION STUDY OF ESOGUARD® ESOPHAGEAL PRECANCER
TESTING ACCEPTED FOR PEER-REVIEWED PUBLICATION
Source text: ID:nPntpx6Ra
Further company coverage: LCID.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Lucid Diagnostics
See all newsBrief: Lucid Diagnostics Begins Receiving Medicare Reimbursement For Esoguard® And Closes $15 Million Financing
Lucid Diagnostics Inc reports results for the quarter ended June 30 - Earnings Summary
Lucid Diagnostics Inc expected to post a loss of 7 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE- Lululemon, United Rentals, cannabis stocks
U.S. STOCKS ON THE MOVE- American Airlines, Pot stocks, Paramount Skydance